Evidence map›Paper›PMID 30477526›Full record

ArticleAIDS research and therapy2018

Long-term virological outcome in children receiving first-line antiretroviral therapy.

Padmapriyadarsini Chandrasekaran, Anita Shet, Ramalingam Srinivasan, G N Sanjeeva, Sudha Subramanyan, Suba Sunderesan, Karunaianantham Ramesh, Bindu Gopalan, Elumalai Suresh, Navaneethan Poornagangadevi and 4 more

Abstract read
In one paragraph

Article in AIDS research and therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Molecular Characterization of theAIDS research and human retroviruses · 2022
    Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Padmapriyadarsini ChandrasekaranDepartment of Clinic Research, ICMR-National Institute for Research in Tuberculosis, No. 1, Mayor Sathyamoorthy Road, Chetpet, Chennai, Tamil Nadu, 600031, India. pcorchids@gmail.com.
Anita ShetJohns Hopkins Bloomberg School of Public Health, Baltimore, USA.
Ramalingam SrinivasanDepartment of Clinic Research, ICMR-National Institute for Research in Tuberculosis, No. 1, Mayor Sathyamoorthy Road, Chetpet, Chennai, Tamil Nadu, 600031, India.
G N SanjeevaIndira Gandhi Institute of Child Health, Bangalore, India.
Sudha SubramanyanDepartment of Clinic Research, ICMR-National Institute for Research in Tuberculosis, No. 1, Mayor Sathyamoorthy Road, Chetpet, Chennai, Tamil Nadu, 600031, India.
Suba SunderesanSt Johns Research Institute, Bangalore, India.
Karunaianantham RameshDepartment of Clinic Research, ICMR-National Institute for Research in Tuberculosis, No. 1, Mayor Sathyamoorthy Road, Chetpet, Chennai, Tamil Nadu, 600031, India.
Bindu GopalanSt Johns Research Institute, Bangalore, India.
Elumalai SureshInstitute of Child Health and Government Hospital for Children, Chennai, India.
Navaneethan PoornagangadeviDepartment of Clinic Research, ICMR-National Institute for Research in Tuberculosis, No. 1, Mayor Sathyamoorthy Road, Chetpet, Chennai, Tamil Nadu, 600031, India.
Luke E HannaDepartment of Clinic Research, ICMR-National Institute for Research in Tuberculosis, No. 1, Mayor Sathyamoorthy Road, Chetpet, Chennai, Tamil Nadu, 600031, India.
Chockalingam ChandrasekarGovernment Hospital of Thoracic Medicine, Chennai, India.
Christine WankeTufts University School of Medicine, Boston, USA.
Soumya SwaminathanIndian Council of Medical Research, New Delhi, India.

Funding

HIV associated Lipodystrophy Syndrome in Children: Role of nutrition, ART & GenesR01AI084390 · NIAID · TUBERCULOSIS RESEARCH CENTRE · PI SWAMINATHAN, SOUMYA · 2011 to 2014
$483k
NIAID NIH HHS R01 AI084390
6 · The paper itself

Abstract

backgroundStudies relating to long-term virological outcomes among children on first-line antiretroviral therapy (ART) from low and middle-income countries are limited.

methodsPerinatally HIV infected, ART-naive children, between 2 and 12 years of age, initiating NNRTI-based ART during 2010-2015, with at least 12 months of follow-up, were included in the analysis. CD4 cell counts and plasma HIV-1 RNA were measured every 24 weeks post-ART initiation. Immunologic failure was defined as a decrease in the CD4 count to pre-therapy levels or below and virologic failure as HIV-RNA of > 1000 copies/ml at 48 weeks after ART initiation. Genotypic resistance testing was performed for children with virologic failure. Logistic regression analysis was done to identify predictors of virologic failure.

resultsThree hundred and ninety-three ART-naïve children living with HIV [mean (SD) age: 7.6 (3) years; mean (SD) CD4%: 16% (8); median (IQR) HIV-RNA: 5.1 (3.5-5.7) log

conclusionsConsiderable immunological improvement is seen in children with ART initiation, but may not be an effective tool to monitor treatment response in the long-term. There is a lack of correlation between immunologic and virologic response while on ART, which may lead to a delay in identifying treatment failures. Periodic viral load monitoring is, therefore, a priority.

Indexed as

HIV-1Viral LoadAntiretroviral Therapy, Highly ActiveCD4 Lymphocyte CountChildChild, PreschoolDrug Resistance, ViralFemaleGenotypeHIV InfectionsHumansMaleMedication AdherenceRNA, ViralSeverity of Illness IndexTreatment FailureRNA, ViralAntiretroviral therapyFirst-linePediatricsTreatment outcomeViral load

Identifiers

PMID30477526
PMCPMC6260781

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.